Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Pharming Group    PHARM   NL0010391025

PHARMING GROUP (PHARM)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:27 pm
0.813 EUR   +4.23%
05/14PHARMING GROUP N.V. : quaterly earnings release
03/02PHARMING GROUP N.V. : annual earnings release
2017PHARMING GROUP N.V. : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
0.7615(c) 0.789(c) 0.786(c) 0.78(c) 0.813(c) Last
12 778 060 9 615 049 6 172 779 5 482 268 11 464 909 Volume
-4.21% +3.61% -0.38% -0.76% +4.23% Change
More quotes
Financials (EUR)
Sales 2018 136 M
EBIT 2018 44,0 M
Net income 2018 20,2 M
Finance 2018 4,80 M
Yield 2018 -
Sales 2019 175 M
EBIT 2019 61,5 M
Net income 2019 34,6 M
Finance 2019 19,3 M
Yield 2019 -
P/E ratio 2018 22,74
P/E ratio 2019 13,57
EV / Sales2018 3,49x
EV / Sales2019 2,63x
Capitalization 482 M
More Financials
Company
Pharming Group specializes in the development of innovative products for the treatment of genetic disorders, specialty products for surgical indications, and nutritional products. The group's technologies include innovative platforms for the production of protein therapeutics, as well as technology... 
More about the company
Surperformance© ratings of Pharming Group
Trading Rating : Investor Rating :
More Ratings
Latest news on PHARMING GROUP
12/11PHARMING : Dutch biotech Pharming plans to challenge big pharma in rare diseases
AQ
12/07PHARMING : reports favourable conclusion from first investigator-initiated direc..
PU
10/25PHARMING : reports interim financial results for the first nine months of 2018
PU
10/18PHARMING : Reports Positive Data From First Investigator-initiated Study of rhC1..
AQ
10/17PHARMING : reports positive data from first investigator-initiated study of rhC1..
PU
09/20PHARMING : FDA rejects Pharmings Ruconest HAE label expansion
AQ
09/20FDA wants extra trial for Pharming's Ruconest as HAE prophylactic
AQ
09/19PHARMING : Receives Complete Response Letter from FDA
PU
08/01PHARMING GROUP : Corporate Officers and Executives' transactions in the company'..
CO
07/30PHARMING : announces further issue of shares as employee options are exercised
PU
More news
Analyst Recommendations on PHARMING GROUP
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PHARMING GROUP
Duration : Period :
Pharming Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMING GROUP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 1,95 €
Spread / Average Target 150%
EPS Revisions
Managers
NameTitle
Sijmen de Vries Chief Executive Officer
Paul Jai Sekhri Chairman-Supervisory Board
Bruno M. L. Giannetti Chief Operations Officer
Robin Wright Chief Financial Officer
Erica Kerkvliet Senior Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PHARMING GROUP-31.10%547
IQVIA HOLDINGS INC24.11%24 306
CELLTRION, INC.--.--%24 149
LONZA GROUP16.86%23 031
INCYTE CORPORATION-28.95%14 320
SEATTLE GENETICS, INC.14.02%9 843